5-(2,4-dimethylphenyl)cyclohexane-1,3-dione | 87822-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(2,4-dimethylphenyl)cyclohexane-1,3-dione
• 英文别名: 5-(2,4-Dimethylphenyl)cyclohexane-1,3-dione
• CAS: 87822-14-8
• 化学式: C₁₄H₁₆O₂
• 分子量: 216.28
• InChiKey: RFTZEIYHIXFYFH-UHFFFAOYSA-N

物化性质

• 沸点：
  388.0±42.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2,4-dimethylphenyl)cyclohexane-1,3-dione 在 对甲苯磺酰叠氮 、 potassium carbonate 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 20.0h， 以70.3%的产率得到2-diazo-5-(2,4-dimethylphenyl)cyclohexane-1,3-dione
  参考文献：
  名称：

  Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network

  摘要：

  Mutation of the metabotropic glutamate receptor type 7 (mGlu7) induces absence -like epileptic seizures, but its precise role in the somatosensory thalamocortical network remains unknown. By combining electrophysiological recordings, optogenetics, and pharmacology, we dissected the contribution of the mGlu7 receptor at mouse thalamic synapses. We found that mGlu7 is functionally expressed at both glutamatergic and GABAergic synapses, where it can inhibit neurotransmission and regulate short-term plasticity. These effects depend on the PDZ-ligand of the receptor, as they are lost in mutant mice. Interestingly, the very low affinity of mGlu7 receptors for glutamate raises the question of how it can be activated, namely at GABAergic synapses and in basal conditions. Inactivation of the receptor activity with the mGlu7 negative allosteric modulator (NAM), ADX71743, enhances thalamic synaptic transmission. In vivo administration of the NAM induces a lethargic state with spindle and/or spike and -wave discharges accompanied by a behavioral arrest typical of absence epileptic seizures. This provides evidence for mGlu7 receptor -mediated tonic modulation of a physiological function in vivo preventing synchronous and potentially pathological oscillations.

  DOI：

  10.3389/fncir.2016.00031
• 作为产物：
  描述：

  2,4-二甲基苯甲醛 在 sodium ethanolate 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 3.5h， 生成 5-(2,4-dimethylphenyl)cyclohexane-1,3-dione
  参考文献：
  名称：

  Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network

  摘要：

  Mutation of the metabotropic glutamate receptor type 7 (mGlu7) induces absence -like epileptic seizures, but its precise role in the somatosensory thalamocortical network remains unknown. By combining electrophysiological recordings, optogenetics, and pharmacology, we dissected the contribution of the mGlu7 receptor at mouse thalamic synapses. We found that mGlu7 is functionally expressed at both glutamatergic and GABAergic synapses, where it can inhibit neurotransmission and regulate short-term plasticity. These effects depend on the PDZ-ligand of the receptor, as they are lost in mutant mice. Interestingly, the very low affinity of mGlu7 receptors for glutamate raises the question of how it can be activated, namely at GABAergic synapses and in basal conditions. Inactivation of the receptor activity with the mGlu7 negative allosteric modulator (NAM), ADX71743, enhances thalamic synaptic transmission. In vivo administration of the NAM induces a lethargic state with spindle and/or spike and -wave discharges accompanied by a behavioral arrest typical of absence epileptic seizures. This provides evidence for mGlu7 receptor -mediated tonic modulation of a physiological function in vivo preventing synchronous and potentially pathological oscillations.

  DOI：

  10.3389/fncir.2016.00031

文献信息

• Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis
  申请人：Kirsch Donald R.

  公开号：US20120264765A1

  公开（公告）日：2012-10-18

  The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.

  本发明涉及提供的环己烷-1,3-二酮（CHD化合物）的鉴定及其制备的药物组合物，用于治疗患有肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的受试者。本发明还提供了制备所述CHD化合物的方法。
• Copper-catalyzed one-pot [3 + 2] cycloadditions of ethynyl indoloxazolidones with 1,3-cyclohexanediones
  作者：Qing-Qiang Su、Ruo-Nan Wang、Yong-Zheng Lv、Ya-Xin Fan、Shan Li、Hong-Li Huang、Ji-Yuan Du

  DOI：10.1039/d3ob00332a

  日期：——

  units in natural products and medicinal molecules, and methods for their introduction are of fundamental importance. Here we report one-pot cycloadditions of ethynyl indoloxazolidones with 1,3-cyclohexanediones enabled by copper catalysis, leading to a series of functionalized furan derivatives in good yields. This method features mild reaction conditions, high efficiency, and wide substrate scope

  稠合呋喃是天然产物和药用分子中常见的单元，引入它们的方法至关重要。在这里，我们报告了通过铜催化实现的乙炔基吲哚恶唑烷酮与 1,3-环己二酮的一锅法环加成，从而以良好的收率生成了一系列功能化的呋喃衍生物。该方法反应条件温和、效率高、底物适用范围广。
• US8722939B2
  申请人：——

  公开号：US8722939B2

  公开（公告）日：2014-05-13
• US9162968B2
  申请人：——

  公开号：US9162968B2

  公开（公告）日：2015-10-20
• US9593069B2
  申请人：——

  公开号：US9593069B2

  公开（公告）日：2017-03-14